29 July 2019
Major Russian pharmaceutical company NovaMedica and the US-based Unipharm have launched a joint project to localize in Russia the production of Melaxen®, a hormone secreted by the pineal gland in a 24-hour circadian rhythm, regulating the normal sleep/wake cycle. Production capacity expected to reach hundreds of thousands of packages per year. It will be enough to meet the requirements of patients living in the territory of the EAEU.
This is the first time Unipharm Corporation decided to localize the production of a Russian portfolio product. And for Nova Medica Innotech it is an important large long-term contract for commercial production in cooperation with an international partner.
The transfer of technology and quality control methods of Melaxen will begin immediately. Onward, after the necessary regulatory procedures, the full production cycle of the finished dosage form of the preparation will be established at the R&D center’s production facilities. Doctors and patients of the countries of the Eurasian Economic Union will have access to Russian-made Melaxen as early as 2020.
“We know how scrupulous Unipharm is about the quality of its products and how carefully it chose a partner for contract manufacturing in Russia. Therefore, we are proud that they have chosen our professionalism, flexibility and technical equipment,” - said Alexander Rudko, head of the R&D Center NovaMedica Innotech.
Unipharm Russia CEO Nikolai Anischenko stated:
“For our company, the decision to localize production is a strategic step. It fully reflects the long-term development plans, both in Russia and in the EAEU space. Our partnership with NovaMedikaInnotech will help increase modern medical care availability, help provide patients with high-quality, modern and affordable medicines, create new jobs.”
The Unipharm Group is an international group of companies established in 1992 with the purpose of providing Eurasian markets with high-quality drugs and nutritional supplements for full satisfaction of customers seeking improvement of life quality. For more than 25 years, Unipharm Group continues to provide award-winning, quality products to customers in different countries.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
New breast cancer guidelines call for first mammogram at age 40 but stop short of annual screening
08 May 2024
WHO proposes recommendations for preventing nitrosamine contamination
07 May 2024
Batyr Berdyklychev is now head of the WHO office in Russia
07 May 2024
Russia expects more medical tourism due to the world’s first drug for ankylosing spondylitis
07 May 2024